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Background: Tobacco control measurements’ had little impact on smoking prevalence in Morocco. The aim of this
study is to provide first data on smoking attributable mortality in Morocco.
Method: The Smoking-Attributable Mortality, Morbidity and Economic Costs (SAMMEC) software was used to
estimate the smoking attributable mortality (SAM) in Casablanca region in 2012. Smoking prevalence and mortality
data of people aged 35 years or older were obtained from the national survey on tobacco “Marta” and from Health
Ministry Mortality System, respectively.
Results: Of the 5261deaths of persons aged 35 years and older, 508 (9.7%) were attributable to cigarette smoking.
This total represents 16.2% of all male deaths (n =448) and 2.0% (n =80) of all female deaths in this region. The
leading four causes of smoking attributable deaths were lung cancer (177), chronic airways obstruction (76),
ischemic heart disease (39), and cerebrovascular disease (31).
Conclusion: Tobacco use caused one out of six deaths in Casablanca in 2012. Four leading causes (lung cancer,
ischemic heart disease, cerebrovascular disease and chronic airways obstruction,) accounted for 51.6% of SAM.
Effective and comprehensive actions must be taken in order to slow this epidemic in Morocco.Background
Scientific evidence of harm caused by smoking has been
accumulating for over 200 years, at first in relation to
cancers of the lip and mouth, and then in relation to
vascular diseases and lung cancer [1]. Cigarette smoking
has been identified as the second leading risk factor for
death from any cause worldwide [2,3]. In 2000, an esti-
mated 4.83 million deaths were attributed to cigarette
smoking globally, with nearly half occurring in the devel-
oping world [4]. In people over age 30, smoking accounts
for one in every five deaths among men and one in every
20 deaths among women globally [5]. The World Health
Organization (WHO) has estimated that approximately
5.4 million people died worldwide from tobacco-related
illnesses in 2006 and says that “unless urgent action is
taken, tobacco’s annual death toll will rise to more than
eight million” by the year 2030 [6]. Because many low-* Correspondence: tachfoutinabil@yahoo.fr
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unless otherwise stated.and middle-income countries are still in early stages of the
tobacco epidemic, the number of smoking-related deaths
in these nations will probably increase during the next
decades. It is estimated that in the period 2002/2030,
tobacco-attributable deaths will decrease by 9% in devel-
oped countries, but increase by 100% (to 6.8 million) in
developing countries [7].
In contrast to deaths which are clearly attributable to
a given factor, for example, accidental deaths, deaths due
to smoking are harder to identify. The number of deaths
caused by tobacco use in a population (the smoking-
attributable mortality, SAM) can be estimated by different
methodologies [8-10]. Peto’s ‘indirect’ method10 used lung
cancer rates to retroactively estimate smoking prevalence
[11]. Malarcher calculated attributable fractions adjusted
for age and other potential confounders [12]. Thun used
the Cox proportional hazard model, incorporating a wide
array of potential confounders [13]. McNulty used smok-
ing status reports from death certificates [14].
The population attributable risk (PAR) methodology is
the most commonly used [8]. PAR incorporates the preva-
lence of smoking and the relative risk (RR) associated withal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Attributable Mortality, Morbidity and Economic Costs
(SAMMEC), an online application developed by the
Centers for Disease Control and Prevention (CDC), use
attributable risk formulas to estimate the number of
deaths from cancer, cardiovascular and respiratory dis-
eases associated with cigarette smoking [15]. SAMMEC
has been applied in United States and other countries
such as Australia [16], Canada [17], Spain [18] Brazil [19],
Israel [20], and Italy [21]. Counting and establishing the
causes of deaths is a matter of concern for the public
health community. Information on deaths is crucial to the
planning, implementation and evaluation of public health
programs at local, national and international levels. In de-
veloped countries, data on major health risk factors are
regularly obtained from population surveys and morbidity
specific registers such as those for cancer. Many devel-
oping countries have reasonably reliable data on mortal-
ity by cause, but lack population data on the prevalence
of risk factors, such as smoking, which are essential to
establish public health policy priorities. Attempts to
produce indirect estimates are needed, because an im-
portant share of the global tobacco burden falls on de-
veloping countries, where 84% of the 1.3 billion current
smokers reside [20].
The Kingdom of Morocco has a surface area of 710
850 km2 and is situated in the north west of Africa with
a population of 29.8 million (Census 2004), with an aver-
age per capita monthly income of $1200. Tobacco control
measurements’ and antismoking legislation had little im-
pact on the prevalence of smoking. A study on cardiovas-
cular risk factors conducted in 2000 found smoking rates
of 17.2% (31.5% for men and 0.6% for women) [22]. In
2006, nationwide smoking-specific studies have been per-
formed looking at prevalence and determinants. The over-
all prevalence of current smoking was 18.5% (31.5% for
males and 3.1% for females) [23]. Among daily smokers,
the proportion of household income spent on tobacco
was around 30% [24]. Moreover, no data is available about
mortality attributable to smoking.
In 2006, a large population-based survey was conducted
in seven Moroccan administrative regions to assess preva-
lence, knowledge and attitude towards tobacco among
Moroccan adult population [22-24]. The results of the sur-
vey allowed, along with other information, to estimate for
the first time the number of smoking attributable deaths in
Casablanca, the biggest city and economic capital of
Morocco. Greater Casablanca is the largest economical re-
gion representing 12% of total population whose 91.6% are
urban and whose population is homogenous. There are 1.7
million men and 63% of the population are less than
35 years old (mean age 25 years). Life Expectancy at birth
is 67.1 years for men and 70.7 for women (Moroccan
Health Ministry, 2003).Methods
Modelization
After considering all the methods that could be used to
estimate smoking attributable fraction (SAF) in Morocco,
we decided to use the population attributable risk (PAR)
method. Direct estimates of mortality cannot be made
because there is a lack of longitudinal studies on the
differential mortality of smokers, former smokers and
non-smokers, necessary to provide RR estimates for
smoking-related diseases and mortality. The smoking
impact ratio (SIR) method proposed by Peto [11] re-
quires lung cancer mortality rates in never smokers,
which are not available in Morocco. SAMMEC method
was used to calculate age-adjusted SAM rates for per-
sons aged 35 years and older, using age, sex and cause
specific mortality rates, current smoking prevalence by
age group and sex (which is available for Morocco), and
the American Cancer Society’s Cancer Prevention Study
II (CPS-II) relative risks [25].
SAM is calculated for each cause of mortality using
the following formula: SAM =OM× PAF; where OM is
the observed (absolute) mortality, and PAF the population
attributable fraction. The following equations were used
to calculate the PAF:
PAF ¼ p0þ p1 RR1þ p2 RR2ð Þ−1ð Þ=
p0þ p1 RR1þ p2 RR2ð Þ;
where p0, p1 and p2 represent the prevalence of non-
smokers, smokers and ex-smokers, respectively. RR1 and
RR2 refer to the risk of dying for smoking related path-
ologies of smokers and ex-smokers respectively com-
pared to a baseline population of non-smokers.
Data sources
Mortality data
The 2012 mortality data for 19 adult smoking-related
diseases were drawn from the Mortality declaration regis-
tries in eight prefectures (administrative department) in
Casablanca. Deaths were categorized by cause, sex and
age group. Diseases were coded according to International
Disease Classifications ICD 10 as shown in, Table 1 [26].
Data on deaths from burns or second hand smoke were
not included in the present study. Causes of death were
distributed into three groups:
 Group I: malignant tumors (lung-trachea-bronchus,
lip-oral cavity-throat, esophagus, larynx, cervix,
bladder and urinary tract, kidney and pancreas);
 Group II: cardiovascular diseases (ischemic heart
disease and cerebrovascular disease in groups aged
35–64 years and >64 years);
 Group III: respiratory diseases (chronic bronchitis
and emphysema).
Table 1 ICD 10 codes for smoking related diseases [26]
Disease category ICD 10
Malignant cancers





Lips, oral cavity, pharynx C00–C14
Neck of the uterus C53
Kidney and renal pelvis C64-C65
Urinary bladder C67
Acute myeloid leukaemia C92.0
Cardiovascular diseases
Ischemic heart disease I20-I25
Cerebrovascular disease < 35 I60–I69
Atherosclerosis I 70
Aortic aneurysm I71
Other arterial disease I72-I78
Other cardiaq diseases I25
Respiratory diseases
Bronchitis, Emphysema J40-J43
Chronic airway obstruction J44–J46
Pneumonia, Influenza J10-J18
Table 2 Relative risk of death for smokers and ex-











Lip, Oral cavity, Pharynx 10.89 3.40 5.08 2.29
Esophagus 6.76 4.46 7.75 2.79
Stomach 1.96 1.47 1.36 1.32
Pancreas 2.31 1.15 2.25 1.55
Larynx 14.60 6.34 13.02 5.16
Trachea, lung, bronchus 23.26 8.70 12.69 4.53
Cervix Uteri 0.00 0.00 1.59 1.14
Kidney and renal pelvis 2.72 1.73 1.29 1.05
Urinary bladder 3.27 2.09 2.22 1.89
Acute myeloid leukemia 1.86 1.33 1.13 1.38
Cardiovascular diseases
Ischemic heart disease
Persons aged 35–64 2.80 1.64 3.08 1.32
Persons aged 65+ 1.51 1.21 1.60 1.20
Other heart disease 1.78 1.22 1.49 1.14
Cerebrovascular disease
Persons aged 35–64 3.27 1.04 4.00 1.30
Persons aged 65+ 1.63 1.04 1.49 1.03
Atherosclerosis 2.44 1.33 1.83 1.00
Aortic aneurysm 6.21 3.07 7.07 2.07
Other arterial disease 2.07 1.01 2.17 1.12
Respiratory diseases
Pneumonia, influenza 1.75 1.36 2.17 1.10
Bronchitis, Emphysema 17.10 15.64 12.04 11.77
Chronic airway obstruction 10.58 6.80 13.08 6.78
Source: Centers for Disease Control and Prevention, Project “Smoking-Attributable
Mortality, Morbidity, and Economic Costs (SAMMEC)”, https://apps.nccd.cdc.gov/
sammec/show_risk_data.asp.
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Smoking prevalence rates for adults aged 35 years or older
were obtained from MARTA survey data [23,27-30]. It is a
national cross-sectional study of a random sample of
9,195 individuals aged 15–90 years conducted in 2006.
The sampling was performed with stratification by region,
socioeconomic level, age and sex, taking into consider-
ation the urban-to-rural ratios in each region. The country
was divided into seven regions: central north region (Fez
and surroundings), occidental region (Casablanca and sur-
roundings), northwest region (Tangier and surroundings),
eastern region (Oujda and surroundings). In each region, a
prefecture (administrative division) was randomly chosen
according to the size of the population. Smoking habit was
defined according to the International Union Against Tu-
berculosis and Lung Diseases guide (Slama 1998). Respon-
dents were classified as smokers if they had smoked at
least 100 cigarettes until the date of the interview (daily
smokers if they daily smoked and occasional smokers if
they smoked on some days), ex smokers if they had
smoked but had quit (for > 3 months), and nonsmokers if
they had never smoked or had smoked fewer than 100 cig-
arettes until the date of the interview. We extracted smok-
ing data in Casablanca region according to gender for
adult population aged ≥35 years.Relative risk of mortality
SAMMEC application uses the American Cancer Society’s
Cancer Prevention Study II (CPS-II) relative risks [24].
The CPS-II is an ongoing prospective study of 1,185,106
residents in United States, aged 30 years or over, for those
who, in 1982, had never smoked regularly, and for those
who were then current cigarette smokers [31]. US Center
for Disease Control and Prevention (CDC) estimates for
smokers and exsmokers are given in Table 2. It shows that
despite smoking cessation leading to substantial reduce
relative risk of mortality, ex smokers are still at a higher
risk than never-smokers. The relative risk ratio of smokers
versus ex-smokers ranges from one unit to 3.2 for the
pathologies in question. Even if the relative risk is reduced
with the passing of time since smoking cessation and
Table 3 Repartition of number of observed deaths due to
smoking related disease according to sex in Casablanca
(2012)
Disease category Observed mortality
Males Females Total
Malignant cancers 309 148 457
Cardiovascular diseases 576 602 1178
Respiratory disease 108 44 152
Total 993 794 1787
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this population has a greater aggregated risk than that
of never-smokers. Table 2 shows mortality relative risk
for smokers and ex-smokers versus nonsmokers accord-
ing to sex and diseases.Results
In 2013, a total of 5261 deaths of individuals aged 35
years and older (2767 males; 2494 females) were reported
in Casablanca. From this total, missing information about
cause of death accounted for 933 of death certificates,
1787 deaths were linked to smoking related diseases (993
men and 794 female) and were taking into account for the
estimation of SAM. Cardiovascular disease caused 1178
deaths, cancer was responsible for 457 deaths, and respira-
tory disease for 152 deaths. Table 3 shows number of ob-
served deaths according to mortality cause and sex. The
prevalence of current and former smoking by sex and two
age groups (35–64 years and ≥ 65 years) are shown in
Table 4. Prevalence’s of smokers and ex-smokers are much
higher among men, with the latter category being gener-
ally higher than the former one, especially among older
adults. Moreover, there are no smokers among women
aged 65 and older. Concerning amount of smoking, 15.6%
of smokers do not smoke daily, and most of the remaining
(75%) smoke more than ten cigarettes per day.
Mortality attributable fraction (MAF) in men varied from
0.1 for cerebrovascular disease (person aged 65 years and
older) to 0.91 for lung cancer and bronchitis and emphy-
sema. In women, it was very lower especially for cardiovas-
cular diseases; the highest SAF for women’s was around
0,44 fir lung and larynx cancers as shown in Table 5.Table 4 Proportion of current, former and nonsmokers accord
Males






35 - 64 32.7 (28.8 – 37.6) 36.3 (31.6 – 41.2) 31.0 (26.5 –
≥65 years 32.5 (18.6 – 49.1) 15.0 (5.7 – 29.8) 52.5 (36.1 –
≥35 years 32.6 (28.4 – 37.4) 34.2 (29.9 – 39.0) 33.2 (28.6 –Of total 5261 deaths recorded in Casablanca in 2012
among person aged 35 years and older, 508 were attrib-
uted to smoking in the three groups of selected causes;
448 men’s and 60 women’s. Smoking accounted for 9.7%
of all deaths; 16.2% of deaths in men, and 2.0% in women.
Cancer was the most frequent cause, responsible for 247
of all smoking attributable deaths, followed by Cardiovas-
cular diseases (160 deaths) and respiratory diseases (101
deaths).
The four leading specific causes of adult smoking attrib-
utable deaths were lung cancer (177 deaths: 159 men’s and
18 women’s), chronic airways obstruction (76 deaths; 62
men’s and 14 women’s), ischemic heart disease (39 deaths:
37 men’s and two women’s), cerebrovascular disease (31
deaths: 28 men’s and three women’s). Combined, these
four conditions were responsible for 63.6% of all SAM
(323/861); 64.0% among men and 61.6% among women’s.
Table 6 presents the number of smoking-attributable
deaths by sex grouped into three broad categories: cancer,
cardiovascular and respiratory diseases.
Males and females differed slightly in the ranking of
the four leading causes of smoking attributable deaths.
Among males they were: lung cancer (159 deaths),
chronic airways obstruction (62 deaths), ischemic heart
disease (IHD) (37 deaths), and cerebrovascular disease
(31 deaths). Among females they were lung cancer (18
death), chronic airways obstruction (14 deaths), athero-
sclerosis (38 deaths), cerebrovascular disease (three deaths).
Table 6 shows Observed mortality (OM) and smoking at-
tributable mortality (SAM) according to sex and related
smoking cause of death.
Discussion
To our knowledge, this is the first study to estimate
SAM in Morocco; cigarette smoking was responsible for
9.7% of all adult deaths (16.2% in men’s and 2.0% in
women’s) and 28.4% of smoking related disease deaths
(45.1% among men’s and 7.6% among women’s) in the
studied population. The current SAM reported in this
paper shows clearly how hazardous and costly in lives
smoking are to a society. Combining the four leading
causes of smoking attributable deaths in Casablanca cit-
ies in 2012; lung cancer, ischemic heart disease, cerebro-
vascular disease and chronic airways obstruction; account










35.8) 89.4 (85.4 – 92.6) 5.5 ( 3.3 – 8.8) 5.2 ( 3.1 – 8.4)
68.5) 100.0 (100.0 – 100.0) 0.0 (0.0 – 13.2) 0.0 (0.0 – 13.2)
37.6) 90.2 (86.6 – 93.1) 5.1 (3.1 – 8.1) 4. 7 (2.8 – 7.8)
Table 5 Smoking attributable fraction according to sex
and diseases
Disease category CID 10 SAF
Malignant cancers Male Female
Trachea, lungs, bronchi C33–C34 0.91 0.43
Esophagus C15 0.76 0.30
Stomach C16 0.33 0.03
Pancreas C25 0.33 0.08
Larynx C32 0.87 0.44
Lips, Oral cavity, Pharynx C00–C14 0.81 0.21
Neck of the uterus C53 xxxx 0.05
Kidney, renal pelvis C64-C65 0.46 0.02
Urinary bladder C67 0.53 0.09
Acute myeloid leukaemia C92.0 0.29 0.01
Cardiovascular diseases
IschemCI heart disease <35 I20-I25 0.46 0.12
>35 0.16 0
Cerebrovascular disease <35 I60–I69 0.46 0.15
>35 0.10 0
Atherosclerosis I 70 0.38 0.05
AortCI aneurysm I71 0.71 0.27
Other arterial disease I72-I78 0.27 0.07
Other cardiaq diseases I25 0.26 0.04
Respiratory diseases
Bronchitis. Emphysema J40-J43 0.91 0.53
ChronCI airway obstruction J44–J46 0.84 0.487
Pneumonia, Influenza J10-J18 0.28 0.07
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ing to Health Ministry statistics, cardiovascular diseases,
cancer and respiratory diseases together were responsible
for 45.8% of all adult deaths in Morocco. Concerning can-
cer deaths, our results are in concordance with Casablanca
cancer registry data (2005–2007) [32]. Incidence data
show that among men lung localization represents 22.7%
of all cancer localization, neck of uterus represents 13.3%
of total female cancer localization. Thus, these results
suggest that a large proportion of these deaths would be
prevented by further reductions in smoking prevalence.
Smoking attributable fraction in men is 6 times higher
comparing to women’s, because the female prevalence of
smoking is 1/7 that of males and RR are similar for sev-
eral disease. Tobacco was responsible for 9.7% of total
deaths among person aged 35 years and older with an
equal male-to-female SAM ratio. It is lower than propor-
tion reported in Argentina (16%) [33], Portugal (11.7%)
[34], Italy (12.5%) [21] and Brazil (13.6%) [19]. Moreover,
in these countries, the most frequents cause of SAM are
Lung cancer, Ischemic heart diseases and chronic ob-
structive airways, representing around more than 50% oftotal SAM. In South Africa, also a developing country,
smoking accounted for 8.0 to 9.0% of deaths, with three
times as many deaths occurring in males compared with
females [35]. Our finding is lower than rate reported in
Taiwan where 1 out of 4 deaths (27%) in middle aged men
(35–69 years old) were attributable to smoking, smoking
rate for adult males in 2001 was 47.3% [36]. Differences in
SAM largely reflect the stage of the smoking epidemic in
each country [37], but the above data show that the num-
ber of cigarettes smoked per day also plays a role. The
SAM in Mexico in 2004 is much lower than the one ob-
served in this work (5.2% of total deaths; 6.0% in men and
4.3% in women) [38]. Because prevalence of smoking in
Mexico is higher than in Morocco, such difference in
SAM is likely to reflect, at least in part, to the lesser
amount of cigarettes smoked daily in Mexico [23].
However, some limitations of the survey need to be
discussed. To estimate smoking attributable mortality, we
used the SAMMEC software. This method uses present
smoking exposure without considering the changing trend
of smoking and latency of mortality causes. In fact, for
most tobacco related diseases, smoking attributable deaths
reflect smoking exposure in previous decades, since la-
tency of lung cancer, other cancers and non-neoplasic
respiratory diseases is of several decades [39]. Thus, the
smoking attributable mortality estimates do not represent
the past or cumulative smoking of the population of inter-
est, but only reflect the current smoking profile [40]. A
major British study [41] that showed the full effects of
tobacco on national mortality rates can take more than 50
years to mature. Another limitation of the SAMMEC
methodology is that it assumes RR estimates from CPS II.
Although this represents one of the largest and best con-
ducted studies to provide RRs of mortality according to
smoking status, the validity of applying the RRs of a US
population to the Moroccan one is open to discussion.
Smoking histories, including in particular intensity and
duration, and tobacco product usage of the CPS II partici-
pants might in fact differ from the Moroccan one, thus in-
fluencing the RRs of various tobacco-related diseases [42].
Environmental factors interacting with smoking are differ-
ent in Morocco, compared to the U.S such as levels of
outdoor pollution and indoor air pollution from cooking
could modify the effects of smoking in Moroccan popula-
tion in a non-multiplicative way [11]. Additionally, effect
of potential confounders such as alcohol (in relation to
some cancers) was not taking into consideration to esti-
mate SAM.
The list of smoking-attributable diseases in SAMMEC
does not include colorectal cancer among the malignan-
cies. Studies in various populations show an association
between tobacco use and colorectal cancer [43,44]. Recent
Nurse’s Health Study evidence found that current smok-
ing was associated with an increased risk of colorectal
Table 6 Observed mortality (OM) and smoking attributable mortality (SAM) according to sex and cause of death
Disease category Males Females Total
Malignant cancers CID 10 OM SAM OM SAM OM SAM
Trachea, lungs, bronchi C33–C34 175 159 41 18 216 177
Esophagus C15 5 4 2 1 7 5
Stamach C16 25 8 25 1 50 9
Pancreas C25 23 8 16 1 39 9
Larynx C32 14 12 2 1 16 13
Lips, Oral cavity, Pharynx C00–C14 11 9 2 1 13 10
Neck of the uterus C53 ==== 38 1 38 1
Kidney, renal pelvis C64-C65 4 2 1 0 5 2
Urinary bladder C67 22 12 3 0 25 12
Acute myeloid leukaemia C92.0 30 9 18 0 48 9
Subtotal 309 223 148 24 457 247
Cardiovascular diseases
IschemCI heart disease <35 I20-I25 30 14 16 2 46 16
>35 146 23 165 0 311 23
Cerebrovascular disease <35 I60–I69 36 17 21 3 57 20
>35 110 11 116 0 226 11
Atherosclerosis I 70 72 27 74 4 146 31
AortCI aneurysm I71 4 3 3 0 7 3
Other arterial disease I72-I78 33 9 36 3 69 12
Other cardiaq diseases I25 145 38 171 6 316 44
Subtotal 576 142 602 18 1178 160
Respiratory diseases
Bronchitis, Emphysema J40-J43 18 16. 6 3 24 19
ChronCI airway obstruction J44 – J46 74 62 30 14 104 76
Pneumonia. Influenza J10-J18 16 5 8 1 24 6
Subtotal 108 83 44 18 152 101
Total 993 448 794 60 1787 508
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the list of tobacco-associated malignancies would further
increase the SAM estimates presented in our work. In
addition, two recent meta-analyses discuss the potential
association between smoking and mortality from tubercu-
losis (TB) [45,46], but this contribution is still controver-
sial, so TB has not been included in the present study.
The potential limitations notwithstanding, the SAMMEC
method had the advantage of allowing relatively fast com-
putation, and enabling comparisons of our estimates with
similarly produced estimates in other countries.
Information about mortality cause was not available
from 17.7% of certificate of deaths which were not tak-
ing into account for total estimation suggesting that our
finding underestimates the SAM. Mathers et al. analyzed
the death registration system of 115 countries to deter-
mine the percentage of causes of deaths coded as un-
known and ill-defined [47]. Based on these results, dataquality for Morocco was categorized as low. However,
the Moroccan Mortality System is far better in Casa-
blanca and has improved considerably in recent years;
we showed that the completeness of data is around 80%.
Thus, the estimates of SAM in the city are likely to ex-
press the actual number of smoking attributable deaths.
Despite these limitations, our results show the import-
ance and the priority to be accorded to measures to re-
duce the rate of smoking in the Moroccan population.
Reducing smoking prevalence would have an important
impact on SAM. A study in Taiwan has demonstrated
that if the annual smoking rate were to be reduced by
10% between 2001 and 2020, the corresponding pro-
jected SAM would decrease by 30%.
A tobacco control law (law 15–91) was enacted in
Morocco in 1996 [48]; it included a ban on advertising,
a ban on sponsorship, and a ban on smoking in public
transport and in educational and healthcare facilities.
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Prevention and Control Program listed up 6 operational
measures on tobacco control.
Conclusion
With Morocco now moving towards ratifying the WHO
Framework Convention on Tobacco Control (FCTC) which
contains comprehensive anti-smoking policies [49], the
need to adapt and enforce effective measure becomes cru-
cial; especially in the following ways:
 More widespread enforcement of current legislation;
 A more complete tobacco control programme in
light of current prevalence and upward trends in
smoking;
 Reinforcing School-based tobacco use prevention
interventions which are effective in reducing
smoking prevalence, reducing smoking initiation and
intended smoking intentions in the short term [50];
 High priority on ensuring that the tobacco industry
does not undermine current and future regulations,
and in future, implementation of FCTC obligations.
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